Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- rivastigmine
- Signifor LAR (pasireotide)
Interactions between your drugs
rivastigmine pasireotide
Applies to: rivastigmine, Signifor LAR (pasireotide)
MONITOR: The risk of significant bradycardia and atrioventricular (AV) block may be increased during concomitant treatment of pasireotide with other drugs that slow heart rate or AV conduction such as beta-blockers, calcium channel blockers, atazanavir, digitalis, flecainide, lacosamide, mefloquine, moricizine, and propafenone.
MANAGEMENT: Pasireotide has not been studied in patients receiving other bradycardic drugs. Because bradycardia and AV block are recognized risk factors for torsade de pointes arrhythmia, electrocardiographic monitoring is recommended prior to initiation of pasireotide and during treatment. Dose adjustments of beta blockers and calcium channel blockers or correction of electrolyte disturbances may be necessary.
References (5)
- (2001) "Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
- Cerner Multum, Inc. "Australian Product Information."
- (2013) "Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Sinemet
Sinemet is used to treat symptoms of Parkinson's disease, such as muscle stiffness, tremors ...
Cogentin
Cogentin is used for extrapyramidal reaction, parkinson's disease
Cosentyx
Cosentyx (secukinumab) is used to treat plaque psoriasis, psoriatic arthritis, ankylosing ...
Exelon
Exelon (rivastigmine) is used to treat dementia caused by Alzheimer's or Parkinson's disease ...
Gocovri
Gocovri (amantadine) is used in the treatment of Parkinson's disease. Includes Gocovri side ...
Trihexyphenidyl
Trihexyphenidyl is used for cerebral spasticity, extrapyramidal reaction, parkinson's disease
Levodopa
Levodopa is used for parkinson's disease, parkinsonism, periodic limb movement disorder, restless ...
Amantadine
Easy-to-read patient leaflet for amantadine. Includes indications, proper use, special ...
Carbidopa/levodopa
Carbidopa/levodopa is used for GTP-CH Deficiency, neuroleptic malignant syndrome, parkinson's ...
Benztropine
Benztropine is used for extrapyramidal reaction, hyperhidrosis, parkinson's disease
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.